Pharmacological issues of linezolid: An updated critical review

Clinical Pharmacokinetics

Volumn 49, Issue 7, 2010, Pages 439-447

  Di Paolo, Antonello ^a   Malacarne, Paolo ^b   Guidotti, Emanuele ^a   Danesi, Romano ^a   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Antibacterials; Burn infections; Children; Cystic fibrosis; Drug interactions; Haemodialysis; Linezolid; Pharmacodynamics; Pharmacokinetics; Renal failure; Sepsis

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; LINEZOLID; RIFAMPICIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL ENDOCARDITIS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; HYPERLACTATEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRION; NONHUMAN; OBESITY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SEPSIS; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; THERMAL INJURY; VANCOMYCIN RESISTANT ENTEROCOCCUS; TOXICITY;

ACETAMIDES; ANTI-INFECTIVE AGENTS; HUMANS; OXAZOLIDINONES; PHARMACOKINETICS; PROTEIN SYNTHESIS INHIBITORS;

EID: 77953336842     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11319960-000000000-00000     Document Type: Review

References (78)

1. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impactonempirical therapy. Clin Microbiol Infect 2008 Dec;14Suppl. 6: 2-8
2. Antony SJ, Bitter KM, Moreland T, et al. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms. Clin Infect Dis 1999 Nov; 29 (5): 1341-1342
3. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis 2000 Jan; 30 (1): 146-151
4. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs 2000 Jan; 59 (1): 7-16
5. Hachem R, Afif C, Gokaslan Z, et al. Successful treatment of vancomycinresistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001 Jun; 20 (6): 432-434
6. Archuleta S, Murphy B, Keller MJ. Successful treatment of vancomycinresistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection. Transpl Infect Dis 2004 Sep; 6 (3): 117-119
7. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42 (13): 1129-1140
8. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002 Mar 14; 346 (11): 867-869
9. Dibo I, Pillai SK, Gold HS, et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 2004 Apr; 42 (4): 1843-1845
10. Craig WA. Does the dose matter? Clin Infect Dis 2001 Sep 15; 33 Suppl. 3: S233-7
11. Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002 Nov; 46 (11): 3484-3489
12. Boak LM, Li J, Rayner CR, et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Anti-microb Agents Chemother 2007 Apr; 51 (4): 1287-1292
13. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 2009 Jan; 10 (1): 2-12
14. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008 Feb; 31 (2): 122-129
15. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44 (10): 1009-1034
16. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003 Sep; 22 (9 Suppl.): S153-7
17. Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008 Jan; 61 (1): 173-176
18. Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007 Jan; 51 (1): 379-382
19. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004 Jan; 48 (1): 281-284
20. Meyer B, Kornek GV, Nikfardjam M, etal. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005 Jul; 56 (1): 172-179
21. Lovering AM, Le Floch R, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009 Mar; 63 (3): 553-559
22. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 2001 Aug; 29 (8): 1136-1145
23. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003 Sep; 47 (9): 2775-2780
24. Meagher AK, Forrest A, Rayner CR, et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003 Feb; 47 (2): 548-553
25. Fiaccadori E, Maggiore U, Rotelli C, et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 2006 May; 21 (5): 1402-1406
26. Pea F, Viale P, Lugano M, et al. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004 Dec; 44 (6): 1097-1102
27. Kraft MD, Pasko DA, DePestel DD, et al. Linezolid clearance during continuous venovenous hemodiafiltration: a case report. Pharmacotherapy 2003 Aug; 23 (8): 1071-1075
28. Mauro LS, Peloquin CA, Schmude K, et al. Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis 2006 Jun; 47 (6): e83-6
29. Tsuji Y, Hiraki Y, Mizoguchi A, et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Che-mother 2008 Apr; 14 (2): 156-160
30. Esposito L, Kamar N, Guilbeau-Frugier C, et al. Linezolid-induced interstitial nephritis in a kidney-transplant patient. Clin Nephrol 2007 Nov; 68 (5): 327-329
31. Vincent JL. Cardiovascular alterations in septic shock. J Antimicrob Chemother 1998 Jan; 41 Suppl. A: 9-15
32. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents 2008 Oct; 32 (4): 294-301
33. Kuang D, Verbine A, Ronco C. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clin Nephrol 2007 May; 67 (5): 267-284
34. Conte Jr JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002 May; 46 (5): 1475-1480
35. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003 Jun; 51 (6): 1431-1434
36. Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res 2002 Apr; 19 (4): 457-462
37. Egle H, Trittler R, Kummerer K, et al. Linezolid and rifampin: Drug interaction contrary to expectations? Clin Pharmacol Ther 2005 May; 77 (5): 451-453
38. Saralaya D, Peckham DG, Hulme B, et al. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J Antimicrob Chemother 2004 Feb; 53 (2): 325-328
39. Blanchet B, Jullien V, Vinsonneau C, et al. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 47 (10): 635-654
40. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001 May; 20 (5): 488-494
41. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003 Jun; 17 (3): 281-299
42. Kearns GL, Abdel-Rahman SM, Blumer JL, et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000 Dec; 19 (12): 1178-1184
43. Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003 Nov; 74 (5): 413-422
44. Kosaka T, Kokufu T, Shime N, et al. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in pae-diatric patients. Int J Antimicrob Agents 2009 Apr; 33 (4): 368-370
45. Hoehn R, Groll AH, Schaefer V, et al. Linezolid treatment of glycopeptideresistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents 2006 Mar; 27 (3): 256-258
46. Santos RP, Prestidge CB, Brown ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pul-monol 2009 Feb; 44 (2): 148-154
47. Smith K, Perez A, Ramage G, et al. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tige-cycline and vancomycin. Int J Antimicrob Agents 2009 Apr; 33 (4): 374-378
48. Molina A, Del Campo R, Maiz L, et al. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylo-coccus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother 2008 Nov; 62 (5): 961-967
49. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 2000 Sep; 28 (9): 1014-1017
50. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007 Mar; 27 (3): 476-9
51. Pea F, Scudeller L, Lugano M, et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006 Feb 1; 42 (3): 434-435
52. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007 Aug; 27 (8): 1081-1091
53. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005 Mar; 39 (3): 427-432
54. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007 Aug; 27 (8): 1189-1197
55. Hachem RY, Hicks K, Huen A, et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 2003 Jul 1; 37 (1): e8-11
56. DeBellis RJ, Schaefer OP, Liquori M, et al. Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. J Intensive Care Med 2005 Nov-Dec; 20 (6): 351-353
57. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. J Am Med Dir Assoc 2004 Mar-Apr; 5 (2): 111-113
58. Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 2005 May; 39 (5): 956-961
59. Strouse TB, Kerrihard TN, Forscher CA, et al. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psycho-pharmacol 2006 Dec; 26 (6): 681-683
60. Beekmann SE, Gilbert DN, Polgreen PM. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 2008 Dec; 62 (4): 407-410
61. Das PK, Warkentin DI, HewkoR, etal. Serotonin syndrome after concomitant treatment withlinezolid and meperidine. Clin Infect Dis 2008 Jan15;46(2): 264-265
62. Hendershot PE, Antal EJ, Welshman IR, etal. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol 2001 May; 41 (5): 563-572
63. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42 (9): 819-850
64. Jacqueline C, Caillon J,Le MabecqueV, etal. Invitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureusbytime-kill curve methods.JAnti-microb Chemother 2003 Apr; 51 (4): 857-864
65. Cha R, Rybak MJ. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1984-1987
66. Sacar M, Sacar S, Kaleli I, et al. Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Surg Res 2007 May 15; 139 (2): 170-175 (Pubitemid 46551167)
67. Tsaganos T, Skiadas I, Koutoukas P, et al. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in anexperimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 2008 Aug; 62 (2): 381-383
68. Malacarne P, Viaggi B, Di Paolo A, et al. Linezolid cerebrospinal fluid concentration in central nervous system infection. J Chemother 2007 Feb; 19 (1): 90-93
69. Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos 2007 Oct; 35 (10): 1816-1823
70. De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006 Apr 15; 42 (8): 1111-1117
71. Javaheri M, Khurana RN, O'Hearn TM, et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007 Jan; 91 (1): 111-115
72. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or betalactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008 Jan; 8 (1): 53-66
73. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003 Jan 15; 36 (2): 159-168
74. Peng GW, Stryd RP, Murata S, et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999 Jun; 20 (1-2): 65-73
75. Buerger C, Joukhadar C, Muller M, et al. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003 Oct 25; 796 (1): 155-164
76. Polillo M, Tascini C, Lastella M, et al. A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit 2010 Apr; 32 (2): 200-205
77. Jacqueline C, Batard E, Perez L, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methi-cillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002 Dec; 46 (12): 3706-3711
78. Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections:aproposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006 Apr; 50 (4): 1599-1602